Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Despite Early Yervoy Success And Promise Of Eliquis, BMS Predicts Overall Net Sales Decline For 2012

This article was originally published in The Pink Sheet Daily

Executive Summary

With top-seller Plavix about to go off-patent in May, Bristol lowers expectations for 2012 sales while talking up its pipeline strength.

You may also be interested in...

Bristol Hopeful Of Quick Reply To Eliquis CRL; Points To Sales Growth Aside From Recent Patent Expiries

With a patent cliff that just turned worse with the patent expiration of Plavix, Bristol-Myers Squibb talked about how it long has planned for these events and says the Amylin transaction positions it to offer a full spectrum of diabetes drugs across three different mechanisms of action.

Dapagliflozin Faces Ominous Prospect Of New Trials

FDA’s rejection of Bristol-Myers Squibb and AstraZeneca’s diabetes drug dapagliflozin may mean new trials are needed, which would be a blow for the drug as well as a bad sign for the new class of SGLT2 inhibitors.

HCV Buyup Continues As Bristol Offers $2.5 Billion For Inhibitex

Driven by a desire to acquire Phase II nucleotide polymerase inhibitor INX-189, the pharma agrees to pay a 163% premium over Inhibitex’s closing share price on Jan. 6.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts